First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.
EP: 1.Personalized Therapy Options Are on the Horizon in Multiple Myeloma
EP: 2.Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 3.Transplant Eligibility in Patients With NDMM
EP: 4.Treatment Considerations for Patients with High-Risk NDMM
Now Viewing
EP: 5.First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
EP: 6.Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
EP: 7.Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
EP: 8.Available Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 9.Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
EP: 10.Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
EP: 11.CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
EP: 12.Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
